These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34246461)

  • 21. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.
    Liao MZ; Prenen H; Dutta S; Upreti VV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):665-672. PubMed ID: 34213592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction and maintenance of procedural sedation in adults: focus on remimazolam injection.
    Chen W; Chen S; Huang Y
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):411-426. PubMed ID: 33686920
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy.
    Pambianco DJ; Borkett KM; Riff DS; Winkle PJ; Schwartz HI; Melson TI; Wilhelm-Ogunbiyi K
    Gastrointest Endosc; 2016 May; 83(5):984-92. PubMed ID: 26363333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial.
    Zhang S; Wang J; Ran R; Peng Y; Xiao Y
    J Clin Pharm Ther; 2022 Jan; 47(1):55-60. PubMed ID: 34655087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users.
    Schippers F; Pesic M; Saunders R; Borkett K; Searle S; Webster L; Stoehr T
    J Clin Pharmacol; 2020 Sep; 60(9):1189-1197. PubMed ID: 32495449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice.
    Masui K; Stöhr T; Pesic M; Tonai T
    J Anesth; 2022 Aug; 36(4):493-505. PubMed ID: 35708787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
    Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
    Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
    J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sedation outcomes for remimazolam, a new benzodiazepine.
    Oka S; Satomi H; Sekino R; Taguchi K; Kajiwara M; Oi Y; Kobayashi R
    J Oral Sci; 2021 Jun; 63(3):209-211. PubMed ID: 34092775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
    Martin P; Oliver S; Gillen M; Marbury T; Millson D
    Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy.
    Pastis NJ; Yarmus LB; Schippers F; Ostroff R; Chen A; Akulian J; Wahidi M; Shojaee S; Tanner NT; Callahan SP; Feldman G; Lorch DG; Ndukwu I; Pritchett MA; Silvestri GA;
    Chest; 2019 Jan; 155(1):137-146. PubMed ID: 30292760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A miniature pig model of pharmacological tolerance to long-term sedation with the intravenous benzodiazepines; midazolam and remimazolam.
    Io T; Saunders R; Pesic M; Petersen KU; Stoehr T
    Eur J Pharmacol; 2021 Apr; 896():173886. PubMed ID: 33493482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remimazolam versus traditional sedatives for procedural sedation: a systematic review and meta-analysis of efficacy and safety outcomes.
    Tang Y; Yang X; Yu Y; Shu H; Xu J; Li R; Zou X; Yuan S; Shang Y
    Minerva Anestesiol; 2022 Nov; 88(11):939-949. PubMed ID: 35785930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.